Computational Approaches for Pharmacovigilance Signal Detection: Toward Integrated and Semantically-Enriched Frameworks

Computational signal detection constitutes a key element of postmarketing drug monitoring and surveillance. Diverse data sources are considered within the ‘search space’ of pharmacovigilance scientists, and respective data analysis methods are employed, all with their qualities and shortcomings, towards more timely and accurate signal detection. Recent systematic comparative studies highlighted not only event-based and data-source-based differential performance across methods but also their complementarity. These findings reinforce the arguments for exploiting all possible information sources for drug safety and the parallel use of multiple signal detection methods. Combinatorial signal detection has been pursued in few studies up to now, employing a rather limited number of methods and data sources but illustrating well-promising outcomes. However, the large-scale realization of this approach requires systematic frameworks to address the challenges of the concurrent analysis setting. In this paper, we argue that semantic technologies provide the means to address some of these challenges, and we particularly highlight their contribution in (a) annotating data sources and analysis methods with quality attributes to facilitate their selection given the analysis scope; (b) consistently defining study parameters such as health outcomes and drugs of interest, and providing guidance for study setup; (c) expressing analysis outcomes in a common format enabling data sharing and systematic comparisons; and (d) assessing/supporting the novelty of the aggregated outcomes through access to reference knowledge sources related to drug safety. A semantically-enriched framework can facilitate seamless access and use of different data sources and computational methods in an integrated fashion, bringing a new perspective for large-scale, knowledge-intensive signal detection.

[1]  Ryen W. White,et al.  Toward Enhanced Pharmacovigilance Using Patient-Generated Data on the Internet , 2014, Clinical pharmacology and therapeutics.

[2]  Patrick B. Ryan,et al.  Big data, big results: Knowledge discovery in output from large‐scale analytics , 2014, Stat. Anal. Data Min..

[3]  David Madigan,et al.  Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[4]  Richard Platt,et al.  The U.S. Food and Drug Administration's Mini‐Sentinel Program , 2012 .

[5]  Patrick B. Ryan,et al.  Empirical Performance of a Self-Controlled Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[6]  Hongfang Liu,et al.  Standardizing adverse drug event reporting data , 2014, J. Biomed. Semant..

[7]  M. Schuemie,et al.  Defining a Reference Set to Support Methodological Research in Drug Safety , 2013, Drug Safety.

[8]  Russ B. Altman,et al.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports , 2012, J. Am. Medical Informatics Assoc..

[9]  G. Omenn,et al.  Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza Vaccines , 2012, PloS one.

[10]  William DuMouchel,et al.  Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases , 2013, Drug Safety.

[11]  Noémie Elhadad,et al.  Natural Language Processing in Health Care and Biomedicine , 2014 .

[12]  Patrick B. Ryan,et al.  Managing Data Quality for a Drug Safety Surveillance System , 2013, Drug Safety.

[13]  Yon Dohn Chung,et al.  A framework to preserve the privacy of electronic health data streams , 2014, J. Biomed. Informatics.

[14]  Carol Friedman,et al.  Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions , 2013, J. Am. Medical Informatics Assoc..

[15]  Christopher D. Manning,et al.  Introduction to Information Retrieval , 2010, J. Assoc. Inf. Sci. Technol..

[16]  G. Niklas Norén,et al.  A Decade of Data Mining and Still Counting , 2010, Drug safety.

[17]  M. Harrison‐Woolrych Evaluating medicines: let's use all the evidence , 2007, The Medical journal of Australia.

[18]  D. Madigan,et al.  Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.

[19]  Régis Beuscart,et al.  Data Mining to Generate Adverse Drug Events Detection Rules , 2011, IEEE Transactions on Information Technology in Biomedicine.

[20]  Michel Dumontier,et al.  Ontology-Based Querying with Bio2RDF’s Linked Open Data , 2013, Journal of Biomedical Semantics.

[21]  Hua Xu,et al.  Identifying Plausible Adverse Drug Reactions Using Knowledge Extracted from the Literature , 2014, AMIA.

[22]  Brent I. Fox,et al.  How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies? , 2013, Drug Safety.

[23]  N. Shah,et al.  Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.

[24]  Martijn J. Schuemie,et al.  Using Electronic Health Care Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods , 2012, Medical care.

[25]  C. Friedman,et al.  Detection of Pharmacovigilance‐Related Adverse Events Using Electronic Health Records and Automated Methods , 2012, Clinical pharmacology and therapeutics.

[26]  Uwe Aickelin,et al.  Comparison of algorithms that detect drug side effects using electronic healthcare databases , 2013, Soft Comput..

[27]  James A. Hendler,et al.  Handbook of Semantic Web Technologies , 2011, Handbook of Semantic Web Technologies.

[28]  Manfred Hauben,et al.  A conceptual approach to the masking effect of measures of disproportionality , 2014, Pharmacoepidemiology and drug safety.

[29]  David Madigan,et al.  Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[30]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[31]  Hua Xu,et al.  Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..

[32]  Susie Stephens,et al.  Applying semantic Web technologies to drug safety determination , 2006, IEEE Intelligent Systems.

[33]  Marie-Christine Jaulent,et al.  Formalizing MedDRA to support semantic reasoning on adverse drug reaction terms , 2014, J. Biomed. Informatics.

[34]  G. Niklas Norén,et al.  Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank , 2014, Drug Safety.

[35]  Hua Xu,et al.  Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records , 2013, J. Am. Medical Informatics Assoc..

[36]  I. Pigeot,et al.  Signal Detection and Monitoring Based on Longitudinal Healthcare Data , 2012, Pharmaceutics.

[37]  M. Lindquist Use of Triage Strategies in the WHO Signal-Detection Process , 2007, Drug safety.

[38]  eHealth for Safety Impact of ICT on Patient Safety and Risk Management , 2007 .

[39]  Vincent Bauchau,et al.  Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm , 2014, Pharmacoepidemiology and drug safety.

[40]  P Ryan,et al.  Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.

[41]  Patrice Degoulet,et al.  Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach , 2005, Int. J. Medical Informatics.

[42]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[43]  Anders Sundström,et al.  Factors Predisposing an Abstract To Be Accepted for Oral Presentation , 2008 .

[44]  Christophe G. Lambert,et al.  Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest , 2014, Drug Safety.

[45]  Patrick B. Ryan,et al.  Alternative Outcome Definitions and Their Effect on the Performance of Methods for Observational Outcome Studies , 2013, Drug Safety.

[46]  Ying Li,et al.  A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records , 2014, J. Am. Medical Informatics Assoc..

[47]  Martijn J Schuemie,et al.  Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD , 2011, Pharmacoepidemiology and drug safety.

[48]  David Madigan,et al.  Empirical Performance of the Case–Control Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[49]  Siddhartha R. Dalal,et al.  Using information mining of the medical literature to improve drug safety , 2011, J. Am. Medical Informatics Assoc..

[50]  Vassilis Koutkias,et al.  Leveraging Post-marketing Drug Safety Research through Semantic Technologies: The PharmacoVigilance Signal Detectors Ontology , 2014, SWAT4LS.

[51]  N. Shah,et al.  Pharmacovigilance Using Clinical Notes , 2013, Clinical pharmacology and therapeutics.

[52]  A. Pariente,et al.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.

[53]  Patrick B. Ryan,et al.  Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases , 2010, J. Am. Medical Informatics Assoc..

[54]  David Madigan,et al.  Disproportionality methods for pharmacovigilance in longitudinal observational databases , 2013, Statistical methods in medical research.

[55]  Andrew M. Jenkinson,et al.  The EBI RDF platform: linked open data for the life sciences , 2014, Bioinform..

[56]  G Niklas Norén,et al.  Pharmacovigilance for a Revolving World: Prospects of Patient-Generated Data on the Internet , 2014, Drug Safety.

[57]  Sally Okun,et al.  Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance , 2013, Drug Safety.

[58]  G. N. Norén,et al.  The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions , 2013, Drug Safety.

[59]  Taha A. Kass-Hout,et al.  Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter , 2014, Drug Safety.

[60]  Prakash M. Nadkarni,et al.  Overcoming barriers to NLP for clinical text: the role of shared tasks and the need for additional creative solutions , 2011, J. Am. Medical Informatics Assoc..

[61]  G. Niklas Norén,et al.  Temporal pattern discovery in longitudinal electronic patient records , 2010, Data Mining and Knowledge Discovery.

[62]  Yen S. Low,et al.  Text Mining for Adverse Drug Events: the Promise, Challenges, and State of the Art , 2014, Drug Safety.

[63]  G Declerck,et al.  Bridging Data Models and Terminologies to Support Adverse Drug Event Reporting Using EHR Data , 2014, Methods of Information in Medicine.

[64]  A Bate,et al.  Decision support methods for the detection of adverse events in post-marketing data. , 2009, Drug discovery today.

[65]  Z. Bankowski,et al.  Council for International Organizations of Medical Sciences , 1991 .

[66]  M. Schuemie,et al.  Variation in Choice of Study Design: Findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) Survey , 2013, Drug Safety.